Scholarlink

<p>Treatment of malignant lymphoma, multiple myeloma, and acute lymphatic leukemia with bispecific antibodies is established. The most important side effect is sustained immunosuppression due to lymphopenia, neutropenia, and hypogammaglobulinemia. Infections with a&#xa0;wide spectrum of pathogens contribute significantly to morbidity and mortality. Febrile neutropenia and bacterial infections of the respiratory tract are most frequent. Due to the considerable cellular immunosuppression, infections with classical opportunistic pathogens such as <i>Pneumocystis jirovecii</i>, herpes simplex virus, varicella zoster virus, <i>Toxoplasma gondii</i> (toxoplasmosis), or the cytomegalovirus are of highest relevance. The current article provides an overview of the frequency of infectious complications during treatment with bispecific antibodies and elaborates on predisposing risk factors. Measures for infection screening and possible drug-based primary prophylaxis are discussed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Infektionen unter Therapie mit bispezifischen Antikörpern bei malignen Lymphomen, dem multiplen Myelom und der akuten lymphatischen Leukämie

  • 期刊论文

  • 发表日期：

    2026年5月5日

查看全文
  • A. Ruckdeschel,
  • J. v. Herder,
  • N. Giesen,
  • M. Sandherr,
  • C. Rieger,
  • D. Teschner

摘要

Treatment of malignant lymphoma, multiple myeloma, and acute lymphatic leukemia with bispecific antibodies is established. The most important side effect is sustained immunosuppression due to lymphopenia, neutropenia, and hypogammaglobulinemia. Infections with a wide spectrum of pathogens contribute significantly to morbidity and mortality. Febrile neutropenia and bacterial infections of the respiratory tract are most frequent. Due to the considerable cellular immunosuppression, infections with classical opportunistic pathogens such as Pneumocystis jirovecii, herpes simplex virus, varicella zoster virus, Toxoplasma gondii (toxoplasmosis), or the cytomegalovirus are of highest relevance. The current article provides an overview of the frequency of infectious complications during treatment with bispecific antibodies and elaborates on predisposing risk factors. Measures for infection screening and possible drug-based primary prophylaxis are discussed.